Leren P, Foss P O, Helgeland A, Hjermann I, Holme I, Lund-Larsen P G
Lancet. 1980 Jul 5;2(8184):4-6. doi: 10.1016/s0140-6736(80)92888-3.
In 23 hypertensive men, aged 47-55, propranolol reduced serum high-density-lipoprotein (HDL) cholesterol by 13% reduced the ratio of HDL to low-density-lipoprotein (LDL)+very-low-density-lipoprotein (VLDL) cholesterol by 15%, increased total triglycerides by 24%, and increased serum uric acid by 10%. Prazosin reduced total serum cholesterol by 9%, LDL+VLDL cholesterol by 10%, and total triglycerides by 16%. These changes are statistically highly significant. On combined treatment with propranolol and prazosin HDL cholesterol was still significantly reduced but changes in other blood lipids were small and insignificant. Uric acid remained elevated. When decisions about long-term therapy are made, such metabolic effects might be of special importance.
在23名年龄在47至55岁之间的高血压男性中，普萘洛尔使血清高密度脂蛋白（HDL）胆固醇降低了13%，使HDL与低密度脂蛋白（LDL）+极低密度脂蛋白（VLDL）胆固醇的比率降低了15%，使总甘油三酯增加了24%，并使血清尿酸增加了10%。哌唑嗪使总血清胆固醇降低了9%，LDL+VLDL胆固醇降低了10%，总甘油三酯降低了16%。这些变化在统计学上具有高度显著性。在普萘洛尔和哌唑嗪联合治疗时，HDL胆固醇仍显著降低，但其他血脂的变化很小且无显著性。尿酸仍保持升高。在做出关于长期治疗的决策时，这种代谢效应可能具有特殊重要性。
